FDA approves first treatment for peanut allergy

pharmafile | February 3, 2020 | News story | Sales and Marketing FDA, FDA Peanuts, peanut, peanut allergy, peanut medicine 

The FDA has approved its first treatment for peanut allergy in patients between ages four and 17.

The drug is Aimmune Therapeutics Inc’s Palforzia, or AR101, and patients must take a daily dose to protect themselves from accidental exposure to peanuts. Its reported list price will be $890 a month. Daniel Adelman, the Chief Medical Officer of Aimmune, said: “Not only is PALFORZIA the first approved therapy for peanut allergy, but it is the first approved therapy for any food allergy.”

The treatment works through specific allergenic proteins that are ingested initially in very small quantities, followed by incrementally increasing amounts. This results in the ability to mitigate allergic reactions over time. The new drug’s doses contain the equivalent of small amounts of peanuts. 

However, the Aimmune Therapeutics Inc warned that the new drug can cause life threatening anaphylaxis, and due to this it will only be available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS).

Peanut allergy is one of the most common food allergies in the world. It affects more than 1.8 million children and teens in the United States and between 1997 and 2008 the number of people allergic tripled.

Conor Kavanagh


Related Content

FDA approves ANDA of 20mg generic Nitisinone capsules

Analog Pharma and Dipharma have announced that the US Food and Drug Administration (FDA) has …

FDA approves Pfizer’s RSV vaccine for older adults

Global pharmaceutical company Pfizer has announced that the US Food and Drug Administration (FDA) has …

Bristol Myers Squibb’s NDA accepted by FDA

Global pharmaceutical company Bristol Myers Squibb (BMS) has announced that its New Drug Application (NDA) …

Latest content